

NCCN Guidelines for Myeloid Growth Factors V.1.2016 – Follow-up on 02/10/2016

Guideline Page and Request	Panel Discussion/References	Institution Vote			
		YES	NO	ABSTAIN	ABSENT
<b>MGF-D (1 of 3) &amp; (2 of 3)</b> Internal request: Consider including tbo-filgrastim as an option in the setting of mobilization and post hematopoietic cell transplant.	Panel consensus supported the addition of tbo-filgrastim for the following:				
	<ul style="list-style-type: none"> <li>As a single agent option for mobilization in the autologous setting.</li> </ul>	13	0	2	11
	<ul style="list-style-type: none"> <li>With a goal of mobilization during count recovery following combination chemotherapy.</li> </ul>	13	1	1	11
	<ul style="list-style-type: none"> <li>In combination with plerixafor in the autologous setting.</li> </ul>	12	1	2	11
	<ul style="list-style-type: none"> <li>As a single agent option for mobilization of allogeneic donors (category 2B).</li> </ul>	10	3	2	11
	<ul style="list-style-type: none"> <li>For granulocyte transfusion (category 2B).</li> </ul>	9	2	4	11
<b>MGF-D (1 of 3)</b> Internal request: Consider including concurrent filgrastim/filgrastim-sndz + sargramostim for mobilization of hematopoietic progenitor cells in the autologous setting.	Based on data in the noted reference, panel consensus supported including concurrent filgrastim/filgrastim-sndz + sargramostim as a category 2B recommendation for mobilization of hematopoietic progenitor cells in the autologous setting.	5	5	5	11
	Reference: 1. Lonial S, Akhtari M, Kaufman J, et al. Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor T cell engraftment with Th1 polarization: results from a randomized clinical trial. <i>Biol Blood Marrow Transplant.</i> 2013;19:460-467.				
<b>MGF-D (1 of 3)</b> Internal request: Consider including plerixafor for the mobilization of allogeneic donors.	Based on data in the noted reference, panel consensus supported including plerixafor as a category 2B recommendation for the mobilization of allogeneic donors.	10	4	1	11
	References: 1. Gattillo S, Markt S, Rizzo L, et al. Plerixafor on demand in ten healthy family donors as a rescue strategy to achieve an adequate graft for stem cell transplantation. <i>Transfusion</i> 2015;55:1993-2000. 2. Schriber J, Fauble V, Sproat LO, Briggs A. Plerixafor 'just in time' for stem cell mobilization in a normal donor. <i>Bone Marrow Transplant</i> 2011;46:1026-1027.				